Dr. Marc Salzberg, MD - CEO, Airway Therapeutics - Novel Biologics For Severe Respiratory Diseases

Dr. Marc Salzberg, MD is President, Chief Executive Officer & Chief Medical Officer of Airway Therapeutics ( https://www.airwaytherapeutics.com/ ), a biopharmaceutical company developing a new class of biologics to break the cycle of injury and inflammation for patients with respiratory and inflammatory diseases.

Dr. Salzberg has more than 25 years of academic and pharmaceutical experience in the management of drug development and clinical research, including medical management of anti-viral drugs clinical development and market introduction including saquinavir and ganciclovir. He spent several years at Roche’s headquarters in Basel, Switzerland as well as its affiliate in Toronto, Canada. As Head of Clinical Cancer Research at the Basel University, he co-founded and managed a clinical research network in Switzerland (CCRC).

During his career, Dr. Salzberg has successfully managed the growth and acquisition of two contract research organizations benefitting shareholders. He was a founder and President of Pharma Brains, a European boutique CRO, which has been acquired by Medpace, a US based global CRO, after 10 years of successful growth under his leadership. He then served as Vice President of Medical Affairs at Medpace.

Dr. Salzberg earned his Medical Doctorate degree from the University of Basel, Switzerland. His medical training and practice include pediatrics/ neonatology and oncology.

#MarcSalzberg #AirwayTherapeutics #HumanSurfactantProteinD #Collectin #PathogenRecognition #RespiratoryDiseases #InflammatoryResponse #BronchopulmonaryDysplasia #ZelpultideAlfa #Covid #Asthma #COPD #Influenza #RSV #ARDS #AcuteRespiratoryDistressSyndrome #ChronicObstructivePulmonaryDisease #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #Research